Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer.
Identifieur interne : 002625 ( PubMed/Corpus ); précédent : 002624; suivant : 002626Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer.
Auteurs : Marc Peeters ; Kelly S. Oliner ; Timothy J. Price ; Andrés Cervantes ; Alberto F. Sobrero ; Michel Ducreux ; Yevhen Hotko ; Thierry André ; Emily Chan ; Florian Lordick ; Cornelis J A. Punt ; Andrew H. Strickland ; Gregory Wilson ; Tudor E. Ciuleanu ; Laslo Roman ; Eric Van Cutsem ; Pei He ; Hua Yu ; Reija Koukakis ; Jan-Henrik Terwey ; Andre S. Jung ; Roger Sidhu ; Scott D. PattersonSource :
- Clinical cancer research : an official journal of the American Association for Cancer Research [ 1078-0432 ] ; 2015.
English descriptors
- KwdEn :
- Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal (administration & dosage), Antineoplastic Combined Chemotherapy Protocols (adverse effects), Antineoplastic Combined Chemotherapy Protocols (therapeutic use), Camptothecin (adverse effects), Camptothecin (analogs & derivatives), Camptothecin (therapeutic use), Colorectal Neoplasms (drug therapy), Colorectal Neoplasms (genetics), Colorectal Neoplasms (mortality), Colorectal Neoplasms (pathology), DNA Mutational Analysis, Exons, Female, Fluorouracil (adverse effects), Fluorouracil (therapeutic use), Genes, ras, Humans, Leucovorin (adverse effects), Leucovorin (therapeutic use), Male, Middle Aged, Mutation, Neoplasm Metastasis, Proportional Hazards Models, Proto-Oncogene Proteins B-raf (genetics), Retreatment, Survival Analysis, Treatment Outcome.
- MESH :
- chemical , administration & dosage : Antibodies, Monoclonal.
- adverse effects : Antineoplastic Combined Chemotherapy Protocols, Camptothecin, Fluorouracil, Leucovorin.
- chemical , analogs & derivatives : Camptothecin.
- drug therapy : Colorectal Neoplasms.
- genetics : Colorectal Neoplasms, Proto-Oncogene Proteins B-raf.
- mortality : Colorectal Neoplasms.
- pathology : Colorectal Neoplasms.
- therapeutic use : Antineoplastic Combined Chemotherapy Protocols, Camptothecin, Fluorouracil, Leucovorin.
- Adult, Aged, Aged, 80 and over, DNA Mutational Analysis, Exons, Female, Genes, ras, Humans, Male, Middle Aged, Mutation, Neoplasm Metastasis, Proportional Hazards Models, Retreatment, Survival Analysis, Treatment Outcome.
Abstract
We evaluated the influence of RAS mutation status on the treatment effect of panitumumab in a prospective-retrospective analysis of a randomized, multicenter phase III study of panitumumab plus fluorouracil, leucovorin, and irinotecan (FOLFIRI) versus FOLFIRI alone as second-line therapy in patients with metastatic colorectal cancer (mCRC; ClinicalTrials.gov, NCT0039183).
DOI: 10.1158/1078-0432.CCR-15-0526
PubMed: 26341920
Links to Exploration step
pubmed:26341920Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer.</title><author><name sortKey="Peeters, Marc" sort="Peeters, Marc" uniqKey="Peeters M" first="Marc" last="Peeters">Marc Peeters</name><affiliation><nlm:affiliation>Antwerp University Hospital and University of Antwerp, Edegem, Belgium. Marc.Peeters@uza.be.</nlm:affiliation></affiliation></author><author><name sortKey="Oliner, Kelly S" sort="Oliner, Kelly S" uniqKey="Oliner K" first="Kelly S" last="Oliner">Kelly S. Oliner</name><affiliation><nlm:affiliation>Amgen Inc., Thousand Oaks, California, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Price, Timothy J" sort="Price, Timothy J" uniqKey="Price T" first="Timothy J" last="Price">Timothy J. Price</name><affiliation><nlm:affiliation>Queen Elizabeth Hospital and University of Adelaide, Woodville, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Cervantes, Andres" sort="Cervantes, Andres" uniqKey="Cervantes A" first="Andrés" last="Cervantes">Andrés Cervantes</name><affiliation><nlm:affiliation>Biomedical Research Institute INCLIVA, University of Valencia, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Sobrero, Alberto F" sort="Sobrero, Alberto F" uniqKey="Sobrero A" first="Alberto F" last="Sobrero">Alberto F. Sobrero</name><affiliation><nlm:affiliation>Ospedale San Martino, Genova, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Ducreux, Michel" sort="Ducreux, Michel" uniqKey="Ducreux M" first="Michel" last="Ducreux">Michel Ducreux</name><affiliation><nlm:affiliation>Institut Gustave Roussy, Villejuif, and Paris-Sud University, Le Kremlin Bicêtre, Paris, France.</nlm:affiliation></affiliation></author><author><name sortKey="Hotko, Yevhen" sort="Hotko, Yevhen" uniqKey="Hotko Y" first="Yevhen" last="Hotko">Yevhen Hotko</name><affiliation><nlm:affiliation>Uzhgorod National University, Uzhgorod, Ukraine.</nlm:affiliation></affiliation></author><author><name sortKey="Andre, Thierry" sort="Andre, Thierry" uniqKey="Andre T" first="Thierry" last="André">Thierry André</name><affiliation><nlm:affiliation>Hôpital Saint Antoine and Université Pierre et Marie Curie (UMPC; Paris VI), Paris, France.</nlm:affiliation></affiliation></author><author><name sortKey="Chan, Emily" sort="Chan, Emily" uniqKey="Chan E" first="Emily" last="Chan">Emily Chan</name><affiliation><nlm:affiliation>Vanderbilt University Medical Center, Nashville, Tennessee, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Lordick, Florian" sort="Lordick, Florian" uniqKey="Lordick F" first="Florian" last="Lordick">Florian Lordick</name><affiliation><nlm:affiliation>University Cancer Center, Leipzig, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Punt, Cornelis J A" sort="Punt, Cornelis J A" uniqKey="Punt C" first="Cornelis J A" last="Punt">Cornelis J A. Punt</name><affiliation><nlm:affiliation>Academic Medical Center, Amsterdam, the Netherlands.</nlm:affiliation></affiliation></author><author><name sortKey="Strickland, Andrew H" sort="Strickland, Andrew H" uniqKey="Strickland A" first="Andrew H" last="Strickland">Andrew H. Strickland</name><affiliation><nlm:affiliation>Monash Medical Center, East Bentleigh, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Wilson, Gregory" sort="Wilson, Gregory" uniqKey="Wilson G" first="Gregory" last="Wilson">Gregory Wilson</name><affiliation><nlm:affiliation>Christie Hospital, Manchester, United Kingdom.</nlm:affiliation></affiliation></author><author><name sortKey="Ciuleanu, Tudor E" sort="Ciuleanu, Tudor E" uniqKey="Ciuleanu T" first="Tudor E" last="Ciuleanu">Tudor E. Ciuleanu</name><affiliation><nlm:affiliation>Institutul Oncologic Ion Chiricuta and University of Medicine and Pharmacy Iuliu Hatieganu, Cluj Napoca, Romania.</nlm:affiliation></affiliation></author><author><name sortKey="Roman, Laslo" sort="Roman, Laslo" uniqKey="Roman L" first="Laslo" last="Roman">Laslo Roman</name><affiliation><nlm:affiliation>Leningrad Regional Oncology Dispensary, Saint Petersburg, Russia.</nlm:affiliation></affiliation></author><author><name sortKey="Van Cutsem, Eric" sort="Van Cutsem, Eric" uniqKey="Van Cutsem E" first="Eric" last="Van Cutsem">Eric Van Cutsem</name><affiliation><nlm:affiliation>University Hospitals and KU Leuven, Leuven, Belgium.</nlm:affiliation></affiliation></author><author><name sortKey="He, Pei" sort="He, Pei" uniqKey="He P" first="Pei" last="He">Pei He</name><affiliation><nlm:affiliation>Amgen Inc., Thousand Oaks, California, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Yu, Hua" sort="Yu, Hua" uniqKey="Yu H" first="Hua" last="Yu">Hua Yu</name><affiliation><nlm:affiliation>Amgen Inc., Thousand Oaks, California, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Koukakis, Reija" sort="Koukakis, Reija" uniqKey="Koukakis R" first="Reija" last="Koukakis">Reija Koukakis</name><affiliation><nlm:affiliation>Amgen (Europe) GmbH, Zug, Switzerland.</nlm:affiliation></affiliation></author><author><name sortKey="Terwey, Jan Henrik" sort="Terwey, Jan Henrik" uniqKey="Terwey J" first="Jan-Henrik" last="Terwey">Jan-Henrik Terwey</name><affiliation><nlm:affiliation>Amgen (Europe) GmbH, Zug, Switzerland.</nlm:affiliation></affiliation></author><author><name sortKey="Jung, Andre S" sort="Jung, Andre S" uniqKey="Jung A" first="Andre S" last="Jung">Andre S. Jung</name><affiliation><nlm:affiliation>Amgen Inc., Thousand Oaks, California, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Sidhu, Roger" sort="Sidhu, Roger" uniqKey="Sidhu R" first="Roger" last="Sidhu">Roger Sidhu</name><affiliation><nlm:affiliation>Amgen Inc., Thousand Oaks, California, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Patterson, Scott D" sort="Patterson, Scott D" uniqKey="Patterson S" first="Scott D" last="Patterson">Scott D. Patterson</name><affiliation><nlm:affiliation>Amgen Inc., Thousand Oaks, California, USA.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:26341920</idno><idno type="pmid">26341920</idno><idno type="doi">10.1158/1078-0432.CCR-15-0526</idno><idno type="wicri:Area/PubMed/Corpus">002625</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002625</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer.</title><author><name sortKey="Peeters, Marc" sort="Peeters, Marc" uniqKey="Peeters M" first="Marc" last="Peeters">Marc Peeters</name><affiliation><nlm:affiliation>Antwerp University Hospital and University of Antwerp, Edegem, Belgium. Marc.Peeters@uza.be.</nlm:affiliation></affiliation></author><author><name sortKey="Oliner, Kelly S" sort="Oliner, Kelly S" uniqKey="Oliner K" first="Kelly S" last="Oliner">Kelly S. Oliner</name><affiliation><nlm:affiliation>Amgen Inc., Thousand Oaks, California, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Price, Timothy J" sort="Price, Timothy J" uniqKey="Price T" first="Timothy J" last="Price">Timothy J. Price</name><affiliation><nlm:affiliation>Queen Elizabeth Hospital and University of Adelaide, Woodville, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Cervantes, Andres" sort="Cervantes, Andres" uniqKey="Cervantes A" first="Andrés" last="Cervantes">Andrés Cervantes</name><affiliation><nlm:affiliation>Biomedical Research Institute INCLIVA, University of Valencia, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Sobrero, Alberto F" sort="Sobrero, Alberto F" uniqKey="Sobrero A" first="Alberto F" last="Sobrero">Alberto F. Sobrero</name><affiliation><nlm:affiliation>Ospedale San Martino, Genova, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Ducreux, Michel" sort="Ducreux, Michel" uniqKey="Ducreux M" first="Michel" last="Ducreux">Michel Ducreux</name><affiliation><nlm:affiliation>Institut Gustave Roussy, Villejuif, and Paris-Sud University, Le Kremlin Bicêtre, Paris, France.</nlm:affiliation></affiliation></author><author><name sortKey="Hotko, Yevhen" sort="Hotko, Yevhen" uniqKey="Hotko Y" first="Yevhen" last="Hotko">Yevhen Hotko</name><affiliation><nlm:affiliation>Uzhgorod National University, Uzhgorod, Ukraine.</nlm:affiliation></affiliation></author><author><name sortKey="Andre, Thierry" sort="Andre, Thierry" uniqKey="Andre T" first="Thierry" last="André">Thierry André</name><affiliation><nlm:affiliation>Hôpital Saint Antoine and Université Pierre et Marie Curie (UMPC; Paris VI), Paris, France.</nlm:affiliation></affiliation></author><author><name sortKey="Chan, Emily" sort="Chan, Emily" uniqKey="Chan E" first="Emily" last="Chan">Emily Chan</name><affiliation><nlm:affiliation>Vanderbilt University Medical Center, Nashville, Tennessee, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Lordick, Florian" sort="Lordick, Florian" uniqKey="Lordick F" first="Florian" last="Lordick">Florian Lordick</name><affiliation><nlm:affiliation>University Cancer Center, Leipzig, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Punt, Cornelis J A" sort="Punt, Cornelis J A" uniqKey="Punt C" first="Cornelis J A" last="Punt">Cornelis J A. Punt</name><affiliation><nlm:affiliation>Academic Medical Center, Amsterdam, the Netherlands.</nlm:affiliation></affiliation></author><author><name sortKey="Strickland, Andrew H" sort="Strickland, Andrew H" uniqKey="Strickland A" first="Andrew H" last="Strickland">Andrew H. Strickland</name><affiliation><nlm:affiliation>Monash Medical Center, East Bentleigh, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Wilson, Gregory" sort="Wilson, Gregory" uniqKey="Wilson G" first="Gregory" last="Wilson">Gregory Wilson</name><affiliation><nlm:affiliation>Christie Hospital, Manchester, United Kingdom.</nlm:affiliation></affiliation></author><author><name sortKey="Ciuleanu, Tudor E" sort="Ciuleanu, Tudor E" uniqKey="Ciuleanu T" first="Tudor E" last="Ciuleanu">Tudor E. Ciuleanu</name><affiliation><nlm:affiliation>Institutul Oncologic Ion Chiricuta and University of Medicine and Pharmacy Iuliu Hatieganu, Cluj Napoca, Romania.</nlm:affiliation></affiliation></author><author><name sortKey="Roman, Laslo" sort="Roman, Laslo" uniqKey="Roman L" first="Laslo" last="Roman">Laslo Roman</name><affiliation><nlm:affiliation>Leningrad Regional Oncology Dispensary, Saint Petersburg, Russia.</nlm:affiliation></affiliation></author><author><name sortKey="Van Cutsem, Eric" sort="Van Cutsem, Eric" uniqKey="Van Cutsem E" first="Eric" last="Van Cutsem">Eric Van Cutsem</name><affiliation><nlm:affiliation>University Hospitals and KU Leuven, Leuven, Belgium.</nlm:affiliation></affiliation></author><author><name sortKey="He, Pei" sort="He, Pei" uniqKey="He P" first="Pei" last="He">Pei He</name><affiliation><nlm:affiliation>Amgen Inc., Thousand Oaks, California, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Yu, Hua" sort="Yu, Hua" uniqKey="Yu H" first="Hua" last="Yu">Hua Yu</name><affiliation><nlm:affiliation>Amgen Inc., Thousand Oaks, California, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Koukakis, Reija" sort="Koukakis, Reija" uniqKey="Koukakis R" first="Reija" last="Koukakis">Reija Koukakis</name><affiliation><nlm:affiliation>Amgen (Europe) GmbH, Zug, Switzerland.</nlm:affiliation></affiliation></author><author><name sortKey="Terwey, Jan Henrik" sort="Terwey, Jan Henrik" uniqKey="Terwey J" first="Jan-Henrik" last="Terwey">Jan-Henrik Terwey</name><affiliation><nlm:affiliation>Amgen (Europe) GmbH, Zug, Switzerland.</nlm:affiliation></affiliation></author><author><name sortKey="Jung, Andre S" sort="Jung, Andre S" uniqKey="Jung A" first="Andre S" last="Jung">Andre S. Jung</name><affiliation><nlm:affiliation>Amgen Inc., Thousand Oaks, California, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Sidhu, Roger" sort="Sidhu, Roger" uniqKey="Sidhu R" first="Roger" last="Sidhu">Roger Sidhu</name><affiliation><nlm:affiliation>Amgen Inc., Thousand Oaks, California, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Patterson, Scott D" sort="Patterson, Scott D" uniqKey="Patterson S" first="Scott D" last="Patterson">Scott D. Patterson</name><affiliation><nlm:affiliation>Amgen Inc., Thousand Oaks, California, USA.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Clinical cancer research : an official journal of the American Association for Cancer Research</title><idno type="ISSN">1078-0432</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Antibodies, Monoclonal (administration & dosage)</term><term>Antineoplastic Combined Chemotherapy Protocols (adverse effects)</term><term>Antineoplastic Combined Chemotherapy Protocols (therapeutic use)</term><term>Camptothecin (adverse effects)</term><term>Camptothecin (analogs & derivatives)</term><term>Camptothecin (therapeutic use)</term><term>Colorectal Neoplasms (drug therapy)</term><term>Colorectal Neoplasms (genetics)</term><term>Colorectal Neoplasms (mortality)</term><term>Colorectal Neoplasms (pathology)</term><term>DNA Mutational Analysis</term><term>Exons</term><term>Female</term><term>Fluorouracil (adverse effects)</term><term>Fluorouracil (therapeutic use)</term><term>Genes, ras</term><term>Humans</term><term>Leucovorin (adverse effects)</term><term>Leucovorin (therapeutic use)</term><term>Male</term><term>Middle Aged</term><term>Mutation</term><term>Neoplasm Metastasis</term><term>Proportional Hazards Models</term><term>Proto-Oncogene Proteins B-raf (genetics)</term><term>Retreatment</term><term>Survival Analysis</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antibodies, Monoclonal</term></keywords><keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term><term>Camptothecin</term><term>Fluorouracil</term><term>Leucovorin</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Camptothecin</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Colorectal Neoplasms</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Colorectal Neoplasms</term><term>Proto-Oncogene Proteins B-raf</term></keywords><keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Colorectal Neoplasms</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Colorectal Neoplasms</term></keywords><keywords scheme="MESH" qualifier="therapeutic use" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term><term>Camptothecin</term><term>Fluorouracil</term><term>Leucovorin</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>DNA Mutational Analysis</term><term>Exons</term><term>Female</term><term>Genes, ras</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Mutation</term><term>Neoplasm Metastasis</term><term>Proportional Hazards Models</term><term>Retreatment</term><term>Survival Analysis</term><term>Treatment Outcome</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">We evaluated the influence of RAS mutation status on the treatment effect of panitumumab in a prospective-retrospective analysis of a randomized, multicenter phase III study of panitumumab plus fluorouracil, leucovorin, and irinotecan (FOLFIRI) versus FOLFIRI alone as second-line therapy in patients with metastatic colorectal cancer (mCRC; ClinicalTrials.gov, NCT0039183).</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26341920</PMID><DateCreated><Year>2015</Year><Month>12</Month><Day>16</Day></DateCreated><DateCompleted><Year>2016</Year><Month>09</Month><Day>15</Day></DateCompleted><DateRevised><Year>2017</Year><Month>03</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1078-0432</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>24</Issue><PubDate><Year>2015</Year><Month>12</Month><Day>15</Day></PubDate></JournalIssue><Title>Clinical cancer research : an official journal of the American Association for Cancer Research</Title><ISOAbbreviation>Clin. Cancer Res.</ISOAbbreviation></Journal><ArticleTitle>Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer.</ArticleTitle><Pagination><MedlinePgn>5469-79</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1158/1078-0432.CCR-15-0526</ELocationID><Abstract><AbstractText Label="PURPOSE">We evaluated the influence of RAS mutation status on the treatment effect of panitumumab in a prospective-retrospective analysis of a randomized, multicenter phase III study of panitumumab plus fluorouracil, leucovorin, and irinotecan (FOLFIRI) versus FOLFIRI alone as second-line therapy in patients with metastatic colorectal cancer (mCRC; ClinicalTrials.gov, NCT0039183).</AbstractText><AbstractText Label="EXPERIMENTAL DESIGN">Outcomes were from the study's primary analysis. RAS mutations beyond KRAS exon 2 (KRAS exons 3, 4; NRAS exons 2, 3, 4; BRAF exon 15) were detected by bidirectional Sanger sequencing in wild-type KRAS exon 2 tumor specimens. Progression-free survival (PFS) and overall survival (OS) were coprimary endpoints.</AbstractText><AbstractText Label="RESULTS">The RAS ascertainment rate was 85%; 18% of wild-type KRAS exon 2 tumors harbored other RAS mutations. For PFS and OS, the hazard ratio (HR) for panitumumab plus FOLFIRI versus FOLFIRI alone more strongly favored panitumumab in the wild-type RAS population than in the wild-type KRAS exon 2 population [PFS HR, 0.70 (95% confidence interval [CI], 0.54-0.91); P = 0.007 vs. 0.73 (95% CI, 0.59-0.90); P = 0.004; OS HR, 0.81 (95% CI, 0.63-1.03); P = 0.08 vs. 0.85 (95% CI, 0.70-1.04); P = 0.12]. Patients with RAS mutations were unlikely to benefit from panitumumab. Among RAS wild-type patients, the objective response rate was 41% in the panitumumab-FOLFIRI group versus 10% in the FOLFIRI group.</AbstractText><AbstractText Label="CONCLUSIONS">Patients with RAS mutations were unlikely to benefit from panitumumab-FOLFIRI and the benefit-risk of panitumumab-FOLFIRI was improved in the wild-type RAS population compared with the wild-type KRAS exon 2 population. These findings support RAS testing for patients with mCRC. Clin Cancer Res; 21(24); 5469-79. ©2015 AACR.See related commentary by Salazar and Ciardiello, p. 5415.</AbstractText><CopyrightInformation>©2015 American Association for Cancer Research.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Peeters</LastName><ForeName>Marc</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Antwerp University Hospital and University of Antwerp, Edegem, Belgium. Marc.Peeters@uza.be.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oliner</LastName><ForeName>Kelly S</ForeName><Initials>KS</Initials><AffiliationInfo><Affiliation>Amgen Inc., Thousand Oaks, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Price</LastName><ForeName>Timothy J</ForeName><Initials>TJ</Initials><AffiliationInfo><Affiliation>Queen Elizabeth Hospital and University of Adelaide, Woodville, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cervantes</LastName><ForeName>Andrés</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Biomedical Research Institute INCLIVA, University of Valencia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sobrero</LastName><ForeName>Alberto F</ForeName><Initials>AF</Initials><AffiliationInfo><Affiliation>Ospedale San Martino, Genova, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ducreux</LastName><ForeName>Michel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institut Gustave Roussy, Villejuif, and Paris-Sud University, Le Kremlin Bicêtre, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hotko</LastName><ForeName>Yevhen</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Uzhgorod National University, Uzhgorod, Ukraine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>André</LastName><ForeName>Thierry</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Hôpital Saint Antoine and Université Pierre et Marie Curie (UMPC; Paris VI), Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chan</LastName><ForeName>Emily</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Vanderbilt University Medical Center, Nashville, Tennessee, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lordick</LastName><ForeName>Florian</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>University Cancer Center, Leipzig, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Punt</LastName><ForeName>Cornelis J A</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>Academic Medical Center, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Strickland</LastName><ForeName>Andrew H</ForeName><Initials>AH</Initials><AffiliationInfo><Affiliation>Monash Medical Center, East Bentleigh, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wilson</LastName><ForeName>Gregory</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Christie Hospital, Manchester, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ciuleanu</LastName><ForeName>Tudor E</ForeName><Initials>TE</Initials><AffiliationInfo><Affiliation>Institutul Oncologic Ion Chiricuta and University of Medicine and Pharmacy Iuliu Hatieganu, Cluj Napoca, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roman</LastName><ForeName>Laslo</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Leningrad Regional Oncology Dispensary, Saint Petersburg, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Cutsem</LastName><ForeName>Eric</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>University Hospitals and KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Pei</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Amgen Inc., Thousand Oaks, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Hua</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Amgen Inc., Thousand Oaks, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koukakis</LastName><ForeName>Reija</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Amgen (Europe) GmbH, Zug, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Terwey</LastName><ForeName>Jan-Henrik</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Amgen (Europe) GmbH, Zug, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jung</LastName><ForeName>Andre S</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>Amgen Inc., Thousand Oaks, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sidhu</LastName><ForeName>Roger</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Amgen Inc., Thousand Oaks, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patterson</LastName><ForeName>Scott D</ForeName><Initials>SD</Initials><AffiliationInfo><Affiliation>Amgen Inc., Thousand Oaks, California, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT00339183</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>09</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Cancer Res</MedlineTA><NlmUniqueID>9502500</NlmUniqueID><ISSNLinking>1078-0432</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>6A901E312A</RegistryNumber><NameOfSubstance UI="C500592">panitumumab</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D048493">Proto-Oncogene Proteins B-raf</NameOfSubstance></Chemical><Chemical><RegistryNumber>Q573I9DVLP</RegistryNumber><NameOfSubstance UI="D002955">Leucovorin</NameOfSubstance></Chemical><Chemical><RegistryNumber>U3P01618RT</RegistryNumber><NameOfSubstance UI="D005472">Fluorouracil</NameOfSubstance></Chemical><Chemical><RegistryNumber>XT3Z54Z28A</RegistryNumber><NameOfSubstance UI="D002166">Camptothecin</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Protocol" UI="C480833">IFL protocol</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Clin Cancer Res. 2015 Dec 15;21(24):5415-6</RefSource><PMID Version="1">26463710</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002166" MajorTopicYN="N">Camptothecin</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs & derivatives</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015179" MajorTopicYN="N">Colorectal Neoplasms</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004252" MajorTopicYN="N">DNA Mutational Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005091" MajorTopicYN="N">Exons</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005472" MajorTopicYN="N">Fluorouracil</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011905" MajorTopicYN="Y">Genes, ras</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002955" MajorTopicYN="N">Leucovorin</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="Y">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009362" MajorTopicYN="N">Neoplasm Metastasis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016016" MajorTopicYN="N">Proportional Hazards Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D048493" MajorTopicYN="N">Proto-Oncogene Proteins B-raf</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019233" MajorTopicYN="N">Retreatment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>03</Month><Day>04</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>06</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>9</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>9</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>9</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26341920</ArticleId><ArticleId IdType="pii">1078-0432.CCR-15-0526</ArticleId><ArticleId IdType="doi">10.1158/1078-0432.CCR-15-0526</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002625 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 002625 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:26341920
|texte= Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:26341920" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |